Liquid Phase Concentrated Growth Factor Versus Conventional Arthrocentesis in Temporomandibular Disc Displacement

Launched by HORUS UNIVERSITY · Jul 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called Liquid Phase Concentrated Growth Factor (LPCGF) to help people with a jaw joint problem known as temporomandibular disorder (TMD), specifically when the disc inside the joint is out of place. The study will compare LPCGF with a standard treatment called arthrocentesis, which involves flushing the joint to reduce pain and improve movement. The goal is to find out if LPCGF is safe and works well as an alternative treatment for this condition.

Adults between 18 and 45 years old who have a diagnosis of disc displacement in one side of their jaw joint, experience symptoms like pain, clicking sounds, or difficulty opening their mouth fully, and have healthy teeth and jaw alignment might be eligible to join. Participants should not have had surgery or injections in the jaw joint before and must be generally healthy without certain medical conditions. If you join the study, you can expect to receive either the new LPCGF treatment or the standard joint flushing, and your progress will be closely monitored to see how well you improve. This study is not yet recruiting, but it aims to provide helpful information for people looking for better ways to treat jaw joint problems.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged 18-45 years. 2. Patients scored as (ASA I).9 3. Presence of complete or nearly complete set of natural dentition with Angle class I occlusion. 4. Diagnosed with unilateral involvement of disc displacement, according to the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD).10 5. Symptoms include one or more of the following: pain, joint sounds, and limited mandibular movement (Maximum Mouth Opening\< 40mm) 6. No prior surgical intervention for TMD. 7. Patient's willingness to participate and follow the study protocol.
• Exclusion Criteria:
• • 1. TMJ pathology related to mechanical deformities 2. Psychiatric problems or presence of systemic diseases that may affect healing (e.g., uncontrolled diabetes, autoimmune disorders, hematologic or neurologic disorders, inflammatory or connective tissue disorders as well as rheumatological or previous infectious diseases, head and neck cancer). 3. Patient unwilling or has contraindication to MRI 4. Previous injections or surgical interventions of the TMJ. 5. Concurrent use of anticoagulants or anti-inflammatory medications within the last 30 days. 6. Pregnant or breastfeeding women. 7. History of trauma or infection in the TMJ region. 8. Allergy to local anesthetics or other components used in the study. 9. Patients diagnosed with (Disc Displacement with reduction with no pain or limited mandibular movements).